Even therapies specifically targeting prevalent tumor mutations, such as the BRAF V600E mutation in melanoma [61] and a variety of EGFR point mutations in lung cancer [62], only lead to relatively short-lived tumor responses. Here, EGFR is linked to lung carcinoma.